Apixaban

Generic Name
Apixaban
Brand Names
Eliquis, Apixaban Accord
Drug Type
Small Molecule
Chemical Formula
C25H25N5O4
CAS Number
503612-47-3
Unique Ingredient Identifier
3Z9Y7UWC1J
Background

Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.

Indication

Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.

Associated Conditions
Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
Associated Therapies
-
Clinical Trials
Related News

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Phase 4
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: apixaban
Drug: warfarin
First Posted Date
2014-03-18
Last Posted Date
2019-04-23
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
66
Registration Number
NCT02090075
Locations
🇺🇸

Los Angeles Biomedical Research Institute, Torrance, California, United States

A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects

First Posted Date
2014-02-28
Last Posted Date
2015-08-13
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
43
Registration Number
NCT02074358

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs

Phase 3
Conditions
Myeloma
Venous Thromboembolism
Interventions
Drug: Apixaban
First Posted Date
2014-02-19
Last Posted Date
2014-12-09
Lead Sponsor
University Hospital, Grenoble
Target Recruit Count
105
Registration Number
NCT02066454
Locations
🇫🇷

Hia Percy, Clamart, France

🇫🇷

Ch La Cote Basque, Bayonne, France

🇫🇷

Chd Vendee, La Roche Sur Yon, France

and more 16 locations

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

First Posted Date
2014-01-29
Last Posted Date
2018-11-20
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
575
Registration Number
NCT02048865
Locations
🇨🇦

William Osler Health System -Brampton, Brampton, Ontario, Canada

🇨🇦

Juravinski Hospital & Cancer Centre, Hamilton, Ontario, Canada

🇨🇦

Kingston General Hospital, Kingston, Ontario, Canada

and more 11 locations

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

First Posted Date
2014-01-13
Last Posted Date
2016-06-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
37
Registration Number
NCT02034591
Locations
🇺🇸

Healthcare Discoveries, LLC D/B/A Icon Development Solutions, San Antonio, Texas, United States

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Apixaban
First Posted Date
2014-01-13
Last Posted Date
2016-08-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
48
Registration Number
NCT02034565
Locations
🇺🇸

Mds Pharma Services, Neptune, New Jersey, United States

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Apixaban
First Posted Date
2014-01-13
Last Posted Date
2016-07-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
75
Registration Number
NCT02034578
Locations
🇺🇸

Parexel Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Phase 4
Completed
Conditions
Atrial Fibrillation
Stroke
Interventions
Drug: Apixaban
Drug: aspirin
First Posted Date
2013-09-10
Last Posted Date
2023-11-15
Lead Sponsor
Population Health Research Institute
Target Recruit Count
4012
Registration Number
NCT01938248
Locations
🇺🇸

Cardiovascular Associates of Mesa, PC, Mesa, Arizona, United States

🇺🇸

St. Vincent Heart Clinic, Little Rock, Arkansas, United States

🇺🇸

Langhorne Cardiology Consultants, Inc., Pensacola, Florida, United States

and more 126 locations

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events

First Posted Date
2013-08-16
Last Posted Date
2013-08-16
Lead Sponsor
Xijing Hospital
Target Recruit Count
10000
Registration Number
NCT01924325
Locations
🇨🇳

Xijing Hospital, Xi'an, Shaanxi, China

Eliquis Regulatory Post Marketing Surveillance (rPMS)

Completed
Conditions
Venous Thromboembolism
Interventions
Drug: Apixaban
First Posted Date
2013-06-25
Last Posted Date
2016-02-08
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
100
Registration Number
NCT01885585
Locations
🇰🇷

Local Institution, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy